Celltrion’s Herzuma (trastuzumab) is the first biosimilar of Roche’s blockbuster HER2-targeted therapy, Herceptin, to launch in Europe. This series tracks uptake of Herzuma and medical oncologists’ awareness of the agent in order to gauge its impact in the commercially lucrative breast cancer market and the gastroesophageal cancer market. The series investigates perceptions of Herzuma, drivers of and barriers to its use, and future-use expectations. Promotional efforts are explored, as well as prescriber and nonprescriber profiles, and benchmarking against other biosimilars, to better understand the dynamics of the German biosimilars market.
QUESTIONS ANSWERED
Are German medical oncologists aware of Herzuma?
What are the drivers of prescribing Herzuma? What is the current level of Herzuma use, and how is that changing over time?
Are German physicians prescribing Herzuma in combination with Perjeta?
Have physicians experienced pressures to prescribe Herzuma to patients?
What promotional messages are sales representatives employing for Herzuma and Herceptin?
PRODUCT DESCRIPTION
Emerging Biosimilars (Germany) is a three-wave series based on primary research data collected at 1 month, 6 months, and 12 months post-commercial launch with German physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
RELEASE DATE
Wave 1: September 2018
Wave 2: TBC 2019
Wave 3: TBC 2019
GEOGRAPHY
Germany
PRIMARY RESEARCH
Survey of 60 medical oncologists
Key metrics included
Unaided and Aided Awareness of Herzuma
Familiarity with and Impressions of Herzuma
Prescriber and Nonprescriber Profiles
Willingness to Prescribe Herzuma
Performance of Herzuma on Key Attributes
Sales Representative Frequency, Reach, and Satisfaction
Benchmarking Against Previously Launched Biosimilars